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Abstract
Background  and  objective:  Istanbul  has  the  highest  incidence  of  tuberculosis  (TB)  in  Turkey.  It
is also  the  largest  city,  with  considerable  differences  in  quality  of  life  across  its  urban  regions.
The aim  of  this  study  is  to  investigate  the  relationship  between  (i)  the  diverse  quality  of  life
across speciﬁc  urban  regions,  (ii)  TB  incidence  rates,  inclusive  of  demographic  and  clinical
characteristics  of  TB  patients,  and  (iii)  adverse  treatment  outcomes.
Methods:  This  retrospective  study  included  23,845  new  TB  patients  (recorded  in  the  National  TB
Registry between  2006  and  2010)  in  Istanbul.  Thirty-nine  urban  districts  of  Istanbul  were  ranked
into ﬁve  groups  on  the  basis  of  an  urban  quality  of  life  index.  Patient  data  were  matched
with these  groups,  and  further  categorized  according  to  ‘age’,  ‘sex’,  ‘country  of  birth’  and
‘antibiotics  resistance’.  Adverse  treatment  outcomes  and  TB  incidence  rates  were  extracted
from ofﬁcial  records.  Logistic  regression,  clustered  analyses,  95%  CI  and  p  values  (STATA)  were
reported  to  describe  the  association  between  variables.
Results:  Six  per  cent  of  total  cases  had  ‘at  least  one  adverse  treatment  outcome’  (default
3.8%, failure  0.5%,  death  1.7%  in  total  cases).  ‘An  adverse  treatment  outcome’  was  found  to  be
associated  with  age  OR  (CI  95%)  (1.02  (1.01--1.03));  ‘male  sex’  1.65  (1.28--2.12);  ‘other  country
of birth’  4.82  (3.05--7.62);  100,000  per  ‘over  60’  insidence  goups  1.61  (1.32-1.97),  the  lowest
quality of  life  index  0.65  (0.47-0.83).
Conclusions:  Patients  with  high  tuberculosis  risk  factors  living  in  high  incidence  regions  need
to be  closely  monitored.  Patients  living  in  lower  ranking  regions  are  more  likely  to  have  ‘poor
treatment  outcomes’.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
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Investigac¸ão  sobre  a  relac¸ão entre  a  qualidade  de  vida  especíﬁca  de  determinada
região  e  resultados  adversos  do  tratamento  à  tuberculose  em  Istambul,  Turquia
Resumo
Contexto  e  objetivo:  Istambul  tem  a  mais  elevada  incidência  de  tuberculose  (TB)  na  Turquia.
É igualmente  a  sua  maior  cidade,  com  diferenc¸as  consideráveis  na  qualidade  de  vida  ao  longo
das suas  regiões  urbanas.  O  objetivo  deste  estudo  é  investigar  a  relac¸ão  entre  i)  as  diversas  qual-
idades de  vida  ao  longo  de  regiões  urbanas  especíﬁcas,  ii)  taxas  de  incidência  de  TB,  incluindo
as características  demográﬁcas  e  clínicas  dos  doentes,  e  iii)  resultados  adversos  do  tratamento.
Métodos:  Este  estudo  retrospetivo  incluiu  23.845  novos  doentes  com  TB  (registados  no  Registo
Nacional de  TB,  entre  2006-2010)  em  Istambul.  Os  trinta  e  nove  distritos  urbanos  de  Istambul
foram classiﬁcados  em  5  grupos  com  base  no  índice  de  qualidade  de  vida  urbano.  Os  dados  dos
doentes foram  correspondidos  com  estes  grupos  e  subsequentemente  divididos  por  categorias  de
acordo com  a  «idade»,  «sexo»,  «país  de  nascimento» e  «resistência  a  antibióticos».  Os  resultados
adversos ao  tratamento  e  as  taxas  de  incidência  de  TB  foram  retiradas  dos  registos  oﬁciais.
Regressão logística,  análises  agregadas,  valores  de  CI  e  p  de  95%  (STATA)  foram  usados  para
descrever  a  associac¸ão  entre  variáveis.
Resultados:  Seis  por  cento  do  total  de  casos  tiveram  pelo  menos  um  resultado  adverso  do
tratamento  (padrão  3,8%;  insuﬁciência  0,5%;  morte  1,7%  do  total  de  casos).  «Um  resultado
adverso  do  tratamento» foi  considerado  como  estando  associado  à  idade  (CI  95%)  (1,02  [1,01-
1,03]); «sexo  masculino» 1,65  (1,28-2,12);  «outro  país  de  nascimento» 4,82  (3,05-7,62);  100.000
por grupos  de  incidência  com  «idade  superior  a  60  anos» 1,61  (1,32-1,97),  o  índice  de  qualidade
de vida  mais  baixo  0,65  (0,47-0,83).
Conclusões:  Os  doentes  com  altos  fatores  de  risco  de  tuberculose  em  regiões  de  elevada  incidên-
cia precisam  de  ser  monitorizados  de  forma  mais  assídua.  Os  doentes  que  vivam  em  regiões  de
classiﬁcac¸ão inferior  têm  maior  probabilidade  de  ter  «maus  resultados  do  tratamento».
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos  os
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Introduction
Even  though  affordable  and  effective  treatment  is  avail-
able,  tuberculosis  is  still  the  cause  of  millions  of  cases  of
active  disease  and  deaths  worldwide.  In  2011,  8.7  million
new  cases  of  active  tuberculosis  (13%  of  which  involved
co-infection  with  the  human  immunodeﬁciency  virus  [HIV])
and  1.4  million  deaths,  including  430,000  deaths  among
HIV-infected  patients  were  recorded.1 In  the  1900s,  the  epi-
demic  of  TB  that  affected  Northern  industrialized  countries
was  mainly  related  to  social,  economic,  and  environmental
factors,  chieﬂy  increasing  population  density  and  urbaniza-
tion.  The  current  epidemic,  however,  which  mainly  affects
developing  countries,  appears  to  result  from  the  combina-
tion  of  pre-existing  socio-economic  determinants  with  new
factors  such  as  HIV,  the  rise  of  antimicrobial  drug  resistance
and  possibly  more  infectious  strains.2--4
The  quality  of  life  index  is  determined  by  the  relationship
between  objective  and  subjective  factors  of  environmen-
tal  and  biological  states,  levels  of  education  and  health
care  facilities.5 Istanbul  is  a  cosmopolitan  city  and  has
the  highest  tuberculosis  incidence  rate  in  Turkey  (44.1  per
100,000  population).  There  is  a  distinct  difference  in  the
quality  of  life  index  across  different  regions  of  the  city.
There  are  many  factors  associated  with  ‘adverse  treatment
outcomes’  such  as  ‘male  sex’,  low  socio-economic  status,
limited  access  to  transportation,  distance  from  home  to
treatment  facilities,  poor  treatment  compliance,  limited
interest  in  information  about  the  disease  and  its  treatment,
presence  of  co-morbidity,  no  follow-up  of  treatment  by
m
T
O
Dedical  staff,  low  income,  alcohol  abuse,  previous  default,
nd  HIV  co-infection.6--12
The  aim  of  this  study  is  to  investigate  the  relationship
etween  the  diverse  quality  of  life  across  speciﬁc  urban
egions,  TB  incidence  rates,  inclusive  of  demographic  and
linical  characteristics  of  TB  patients,  and  adverse  TB  treat-
ent  outcomes  in  Istanbul.
ethods
his  retrospective  cohort  study  included  23,845  new  TB
atients,  recorded  in  the  National  TB  Registry  between
006  and  2010.  Patients  were  excluded  from  the  study  if
hey  were  currently  under  treatment  (multidrug-resistant
B  treated  with  second-line,  non-tuberculosis  mycobacte-
ia  (n  =  747));  had  a  ‘previous  treatment  history’  (n  =  2397);
ere  ‘transfer  in’  patients  (n  =  592)  or  ‘transfer  out’  patients
n  =  1694).  All  remaining  TB  patients  (23,845)  were  included
n  this  study.
New  patients  were  deﬁned  as  those  who  had  ‘no  pre-
ious  treatment’  for  TB,  or  who  had  taken  anti-TB  drugs
or  less  than  1  month.  New  patients  with  pulmonary  TB
eceived  a  standardized  short-course  chemotherapy,  con-
isting  of  two  months  of  isoniazid  (H),  rifampicin  (R),
yrazinamide  (Z),  and  ethambutol  (E),  followed  by  four
onths  of  just  HR.  Patients  were  followed  up  monthly  at
B  dispensaries,  and  received  TB  drugs  under  DOTS  (Directly
bserved  Treatment,  Short-course)  every  day  at  the  nearest
OTS  facility.13,14
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TB  treatment  in  Turkey  involves  no  direct  cost  to  patients
nd  is  provided  by  dedicated  TB  dispensaries  where  treat-
ent  outcomes  are  monitored  through  case  registries,
acilitating  comprehensive  assessment  of  TB  epidemiology
nd  treatment  results.
Clinical  treatment  outcomes  are  deﬁned  as:  ‘treatment
ailure’  --  a  patient  whose  sputum  smear  or  culture  is  pos-
tive  at  5  months  or  later  during  treatment;  patients  found
o  harbour  a  multidrug-resistant  strain  at  any  point  of  time
uring  treatment  (smear  positive  or  negative);  ‘death’  --
 patient  who  dies  for  any  reason  during  the  course  of
reatment;  and  ‘default’  --  a  patient  whose  treatment  was
nterrupted  for  two  consecutive  months  or  more.  In  this
tudy,  clinical  outcome  was  evaluated  12  months  after
ommencement  of  treatment.  Default,  death,  and  treat-
ent  failure  outcomes  were  grouped  together  as  ‘adverse
utcomes’.13
Research  carried  out  by  the  Istanbul  Chamber  of
ommerce  in  2009,  determined  a  ‘Quality  of  Life  Index’,
hich  derived  from  the  calculation  of  the  arithmetical  mean
f  7  indices,  for  each  of  the  39  regions  in  the  study.  The
 indices  were  obtained  from  statistical  data  encompassing:
emographic  structure  (Turkish  Statistics  Institute);  Educa-
ion  (The  local  educational  authority);  Health  (The  Public
ealth  authority);  Economy  (The  Chamber  of  Commerce  Tax
fﬁce  HQ,  Central  Bank,  property  market);  Transportation
nd  Accessibility  (Public  Transport  ofﬁces);  Environment
electric/gas/water  boards);  and  Social  life  (The  ministry
f  Culture  and  Tourism).  The  39  regions  were  further  cate-
orized  into  ﬁve  groups  according  to  these  indices  (the  1st
ategory  having  the  highest  quality  of  life5)  which  forms  the
asis  of  our  study.  Our  patients  were  treated  in  their  regional
ispensary  and  coded  according  to  the  ﬁve  groupings  of  the
uality  of  life  index.
TB  incidence  rates  for  speciﬁc  regions  in  Istanbul
etween  2006  and  2010  were  obtained  from  the  public
ealth  directorate  of  Istanbul.  TB  regional  incidence  rate
as  grouped  into  three  (100,000  per  20--40,  40--60,  60>).
emographic  and  clinical  characteristics  of  TB  patients  were
ategorized  into  age  groups  (0--18,  18--35,  36--50,  51--65,
65);  gender;  country  of  birth  (Turkey  or  other  country);
nd  antibiotics  resistance  (any  resistance,  HR  resistance).
tatistical  analysis
ategorical  variables  were  summarized  using  proportions.
ogistic  regression,  clustered  analyses  yielding  odds  ratios,
5%  CI  and  p  values  (STATA)  were  reported  to  describe  the
ssociation  between  variables  (speciﬁc  regions  and  quality
ife  index  and  its  inﬂuence  on  TB  incidence  rate,  inclusive
f  demographic  and  clinical  characteristics  of  TB  patients)
nd  adverse  treatment  outcomes.
ata  collection
here  are  32  TB  dispensaries  in  Istanbul,  and  each
ollaborates  with  one  of  the  two  main  diagnostic  lab-
ratories,  subject  to  external  quality  control  from  the
ational  TB  reference  laboratory  in  Ankara.  The  National
uberculosis  database  follows  the  WHO  country  report
CISID)  and  case-based  recording  data  standards  (Euro  TB
‘
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ata  ﬁle).  To  reduce  bias,  20  cases  from  the  computerized
atabase  were  randomly  chosen  to  check  against  the  original
egistry  to  evaluate  quality  of  data.
Ethical  approval  for  the  study  was  obtained  from  the
nstitutional  review  board  of  Istanbul  University  in  accor-
ance  with  the  Helsinki  recommendations  (approval  no.
011/1543-718).
esults
aseline  characteristics  of  the  cases  were  summarized  in
able  1. Of  the  total  of  23,845  patients,  48.3%  of  cases  were
8--35  year  old,  60.4%  of  cases  were  male.  1.3%  of  cases
ere  from  another  country  of  birth.  36.3%  of  cases  were
esistant  to  at  least  one  drug.  38.4%  of  the  cases  occurred  in
reas  which  had  over  60  incidences.  The  lowest  rate  (0.6%)
f  ‘other  country  of  birth’  was  found  to  be  in  the  lowest
uality  of  life  group.  ‘Resistance  to  at  least  one  antibiotic’
aried  from  42.8%  to  30.5%  in  the  QOL1  to  QOL5  groupings.
he  lowest  ‘resistance’  rate  (30.5%)  was  found  to  be  in  the
owest  quality  of  life  group.  QOL1  to  QOL5  has  15.9--77%
over  60’  per  100,000  incidences.  77%  of  over  those  in  the
0  per  100,000  incidences  were  in  the  lowest  quality  of  life
roup.
6%  of  total  cases  had  ‘some  adverse  treatment  outcome’
default  was  3.8%,  failure  was  0.5%,  death  was  1.7%  in  total
ases).  Most  of  the  total  cases  (42.3%)  were  in  QOL3.  ‘Some
dverse  treatment  outcome’  was  10.0--39.9%  in  the  QOL1  to
OL5  groupings.  The  highest  rate  of  adverse  treatment  was
n  QOL3  (Table  2).
‘Some  form  of  adverse  treatment  outcome’  and  ‘death’
ere  found  to  be  signiﬁcant  with  increasing  age  (1.02
1.01--1.03),  1.07  (1.06--1.08)).  Some  kind  of  ‘adverse  treat-
ent  outcome’  was  found  to  be  signiﬁcant  in  males  (1.65
1.28--2.12))  and  ‘default’  was  found  to  be  signiﬁcant  (2.08
1.59--2.72))  in  males.  ‘Some  kind  of  adverse  treatment
utcome’  was  found  to  be  signiﬁcant  (4.82  (3.05--7.62))  in
other  country  of  birth’.  Default  was  signiﬁcant  in  ‘other
ountry  of  birth’  5.70  (3.76--8.62).  ‘Some  adverse  treatment
utcome’  was  found  to  be  signiﬁcant  (1.61  (1.32--1.97))  in
over  60’  for  100.000  groups  and  ‘default’  was  found  to  be
igniﬁcant  2.66  (1.80--3.92)  in  ‘over  60’  for  100,000  groups.
Failure  of  treatment  outcome’  was  found  to  be  signiﬁcant
3.14  (1.93--5.09))  in  drug  resistance  strains.  ‘Some  form
f  adverse  treatment  outcome’  and  ‘default’  were  found
o  be  signiﬁcantly  lower  in  the  lowest  quality  of  life  (0.65
0.47--0.83),  0.38  (0.26--0.56))  (Table  3).
iscussion
n  this  study,  6%  of  total  new  cases  had  ‘some  kind  of
dverse  treatment  or  outcome’  (default  was  3.8%,  failure
as  0.5%,  death  was  1.7%).  ‘Death’  was  found  to  be  sig-
iﬁcant  with  increasing  age.  ‘Default’  was  approximately
wo-fold  in  males  and  was  found  to  be  six-fold  in  ‘other
ountry  of  birth’  category.  ‘Default’  was  found  to  be  approx-
mately  three-fold  in  ‘over  60’  incidence  for  100,000  groups.
Failure  of  treatment  outcome’  was  found  to  be  three-fold
n  drug  resistant  strains.  ‘Default’  was  found  to  be  signiﬁ-
antly  lower  in  the  lowest  quality  of  life  group.  The  lowest
other  country  of  birth’  rate  (0.6%)  was  found  to  be  in
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Table  1  Quality  of  life  (QOL)  groups,  demographics  and  clinical  characteristics  of  tuberculosis  patients.
Case  characteristic Total  cases  QOL1  QOL  2  QOL  3  QOL4  QOL5
(%) (%)  (%)  (%)  (%)  (%)
Number  of  cases  23,845  2962  2461  10,085  3920  4417
Age group
0--18  10.0  11.0  10.4  12.6  15.8  19.8
18--35 48.3  46.2  44.8  48.5  50.5  49.4
36--50 19.6 21.3  21.1  20.4  18.1  17.3
51--65 12.0 13.2 15.5 12.2  11.1  9.8
>65 6.0 8.2 8.1 6.4 4.5  3.6
Gender
Male 60.4  60.6  61.1  59.8  60.7  60.9
Country of  birth
Other  country  1.3  2.1  2.3  1.1  1.1  0.6
Antibiotic resistance
Sensitive  63.1 63.0 61.1  61.0  64.4  69.5
Any resistance 36.3 37.0 38.9  42.8  35.6  30.5
TB incidence
20--40  26.0  33.0  45.6  40.1  4.0  0
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t40--60 35.6  20.6  
60> 38.4  46.4  
the  lowest  quality  of  life  group.  The  lowest  ‘resistance’
rate  (30.5%)  was  found  to  be  in  the  lowest  quality  of  life
group.
TB  is  almost  always  curable  if  patients  are  treated
with  effective,  uninterrupted  anti-tuberculosis  treatment,
which  is  crucial  in  controlling  the  spread  of  infection  and
minimizing  the  development  of  drug  resistance.  The  rate
of  ‘treatment  success’  for  smear-positive  cases  treated,
exceeded  the  WHA  global  target  for  the  ﬁrst  time  in
2007  (86%  globally).15 Since  2006  (after  the  expansion  of
DOT  in  Turkey),  ‘treatment  success’  rate  is  continuing  to
improve.16 In  2008,  ‘treatment  success’  was  achieved  in
92%  of  smear  positive  new  cases.16 Statistics  in  Turkey
(2005--2008)  displayed  consistent  reduction  in  ‘treatment
default’  of  5.7--3.2%  and  reduction  in  ‘adverse  treatment
17--20outcome’  of  19.2%  between  1998  and  2000  in  Istanbul. In
our  study,  new  TB  cases  were  evaluated  and  the  default  rate
(3.8%)  was  found  to  be  higher  than  the  other  ‘any  adverse
treatment  outcomes’.
o
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Table  2  Treatment  outcomes  according  to  quality  of  life  indices  
Total  cases
(%)
Any  adverse
treatment  outcome
(%)
Defa
Number  of
cases,  N  (%)  23,845
(100)
Yes
1433  (6)
No
22,412
(94)
Yes
918  (3.8)
QOL  1 12.4  14.2  12.3  14.6  
QOL 2 10.3 10.0  10.3  9.2  
QOL 3 42.3  39.9  42.4  37.5  
QOL 4  16.4  21.1  16.1  24.4  
QOL 5  18.5  14.8  18.8  14.4  28.0  44.0  46.6  22.2
26.4  15.9  49.5  77.8
Upon  evaluation  by  systematic  review,21 it  was  found
hat  four  major  factors  interact  which  affect  adherence
o  TB  treatment  including:  structural  factors;  poverty
nd  gender  discrimination;  social  context;  health  service
actors;  and  personal  factors.  Gender  differences  in  tuber-
ulosis  epidemiology  may  arise  either  as  a  consequence
f  differences  in  biological  functioning  or  differences  in
he  societal  roles  of  men  and  women.22 In  our  study,
adverse  treatment  outcome’  and  ‘default’  were  found
o  be  approximately  two-fold  in  males.  The  increased
isk  of  ‘adverse  treatment  outcome’  and  ‘default’  among
mmigrants  is  recorded  in  ‘other  country’.23,24 In  our
ational  study,  ‘birth  outside  Turkey’  was  associated  with
 more  than  ﬁve-fold  increase  in  the  odds  of  ‘adverse
reatment  outcome’.25,26 In  this  study,  ‘birth  outside
f  Turkey’  was  associated  with  an  approximately  six-
old  increase  and  ‘male  gender’  was  associated  with  a
wo-fold  increase  in  the  odds  for  ‘default  treatment  out-
ome’.
(QOL).
ult  (%)  Treatment  failure  (%)  Death  (%)
No
22,927
(96.2)
Yes
119  (0.5)
No
23,726
(99.5)
Yes
397  (1.7)
No
23,448
(98.3)
12.3  15.1  12.4  13.1  12.4
10.4  11.8  10.3  11.3  10.3
42.5  35.3  42.3  46.9  42.2
16.1  16.0  16.4  14.9  16.5
18.7  21.8  18.5  13.9  18.6
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Table  3  Multivariable  logistic  and  cluster  analysis  for  adverse  treatment  outcomes  and  effecting  factors  (OR  (CI  95%)).a
Any  adverse  treatment
outcome
Default  Failure  Death
Age,  years  1.02  (1.01--1.03)  1.00  (0.99--1.01)  0.99  (0.98--1.00)  1.07  (1.06--1.08)
Female --  --  --  --
Male 1.65  (1.28--2.12)  2.08  (1.59--2.72)  1.57  (0.78--3.15)  1.18  (0.78--1.78)
Birth in  Turkey  --  --  --  --
Other country  of  birth 4.82  (3.05--7.62)  5.70  (3.76--8.62)  2.83  (0.91--8.75)  1.18  (0.27--5.05)
TB incidence  (20--40) -- -- -- --
TB incidence  (40--60) 1.29  (1.03--1.63) 1.76  (1.20--2.58) 0.68  (0.34--1.35) 1.02  (0.40--1.61)
TB incidence  (over  60) 1.61  (1.32--1.97) 2.66  (1.80--3.92) 0.50  (0.25--1.02) 0.78  (0.52--1.73)
Sensitive --  --  --  --
Any resistance  1.40  (1.15--1.71)  1.20  (0.92--1.58)  3.14  (1.93--5.09)  1.12  (0.86--1.46)
QOL 1  --  --  --  --
QOL 2  0.88  (0.68--1.14)  0.79  (0.54--1.16)  0.83  (0.42--1.61)  1.39  (0.91--2.11)
QOL 3 0.82  (0.60--1.11) 0.69  (0.41--1.17) 0.82  (0.36--1.86) 1.45  (0.96--2.02)
QOL 4 0.95  (0.59--1.53) 0.87  (0.50--1.52) 1.24  (0.56--2.70) 1.18  (0.69--2.02)
QOL 5 0.62  (0.47--0.83) 0.38  (0.26--0.56) 2.11  (0.96--4.65) 1.36  (0.85--2.19)
a
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Conﬁdentiality  of  data.  The  authors  declare  that  they  havea Multivariable logistic and cluster analyses.
‘Over  60’  was  strongly  associated  with  death  in  an
nalysis  of  TB  treatment  outcomes  involving  15  European
nion  (EU)  countries.27 In  our  study,  ‘some  adverse  treat-
ent  outcome’  and  ‘death’  were  found  to  be  signiﬁcant.
nternational  studies  highlight  the  importance  of  antibiotic
esistance  in  treatment  outcomes.  Espinal  et  al.  reported
ncreased  risks  of  ‘treatment  failure’  and  ‘mortality’  among
ew  TB  cases  with  MDR  in  6  countries  in  the  Caribbean
egion,  Asia,  Europe,  and  South  America.28 In  recent  stud-
es  carried  out  in  Istanbul,  ‘antibiotic  resistance’  had  the
trongest  impact  on  outcome.  Patients  with  MDR  strains  had
ver  90-fold  increased  odds  of  ‘treatment  failure’  and  nearly
-fold  increased  odds  of  ‘death’.25 ‘Any  kind  of  resistance’
ad  three-fold  increased  odds  of  ‘some  adverse  treatment
utcome’.26 ‘Failure  of  treatment  outcome’  was  found  to  be
hree-fold  in  drug  resistance  strains.
WHO  has  recently  highlighted  the  importance  of  biologi-
al  and  socio-economic  factors  in  driving  the  epidemic  of  the
new  TB’,  and  studies  challenge  the  impact  of  the  current
lobal  strategy  for  the  control  of  TB,  based  on  case  ﬁnd-
ngs  and  treatment.29--31 Many  components,  such  as  health,
dequate  nutrition  and  protection,  access  to  education,  sex-
al  equality  and  lack  of  negative  impact,  contribute  to  the
uality  of  an  individual’s  life.  In  this  study,  seven  indices
ere  utilized  for  determining  quality  of  life  (demographi-
al  structure,  education,  health,  economy,  transportation
nd  accessibility,  environment  and  social  life)5 and  it  was
ound  that  ‘some  form  of  adverse  treatment  outcome’  and
default’  were  lower  in  the  lowest  quality  of  life  region.
atient  treatment  compliance  was  seen  to  be  high  in  the
ower  quality  of  life  regions.  The  study  also  revealed  that  in
he  lowest  quality  of  life  regions,  ‘resistance  to  at  least  one
ntibiotic’,  and  ‘other  country  of  birth’  rates  were  lower
han  in  the  higher  quality  of  life  regions.
The  strength  of  this  study  is  that  it  was  carried  out  in
stanbul,  Turkey’s  largest  city,  with  the  country’s  highest
ncidence  of  TB.  The  study  included  all  eligible  patients
ithin  the  city  catchment  area,  minimizing  the  effect  of
election  bias.
f
t
s
iThe  limitations  of  this  study  included:  ﬁrstly,  TB  patients
ho  were  not  detected  by  the  national  health  system  could
ot  be  included  and  although  this  group  is  small  it  is  also
ikely  to  include  marginalized  groups  such  as  the  home-
ess.  Secondly,  patients  were  transferred  out,  and  follow-up
nformation  was  unavailable.  Finally,  the  living  conditions
nd  socio-economic  factors  vary  considerably  according  to
istrict  within  the  regions  of  Istanbul,  which  could  not  be
valuated  in  this  study.
Signiﬁcant  ﬁndings  in  this  study  include  a  ‘treatment
uccess’  rate  of  92.8%  and  identiﬁcation  of  patient  charac-
eristics  associated  with  ‘adverse  outcomes’.  These  ﬁndings
uggest  several  recommendations  for  improving  care  among
B  patients.  Patients  with  characteristics  of  ‘advanced  age’,
male  sex’,  ‘birth  outside  of  Turkey’,  prevalence  of  ‘antibi-
tic  resistance’  should  be  considered  a  high  risk  for  ‘adverse
utcomes’,  justifying  more  increased  awareness  and  care.
Patients  living  in  high  TB  incidence  regions  need  to  be
onitored  more  closely.  This  study  also  showed  that  region
n  relation  to  the  quality  of  life  index  could  affect  the  TB
reatment  outcomes;  however,  for  a  more  accurate  evalua-
ion  details  of  the  TB  patient’s  speciﬁc  district  of  abode  and
iving  conditions,  within  the  regional  category,  need  to  be
aken  into  account.
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